Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).

Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.

Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.

Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days